About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including ... [Read more]
Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 895
Stock Exchange NASDAQ
Ticker Symbol MDXG
Full Company Profile
Financial Performance
Financial Statements
Analyst Forecast
According to 5 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 91.69% from the latest price.
Price Target
$12.0
(91.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts
News
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of lead...
16 days ago - GlobeNewsWire
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA wa...
16 days ago - GlobeNewsWire
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process
25 days ago - GlobeNewsWire
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has...
7 weeks ago - GlobeNewsWire
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following in...
3 months ago - GlobeNewsWire
MIMEDX Announces First Quarter 2024 Operating and Financial Results
Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host...
3 months ago - GlobeNewsWire
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first qu...
4 months ago - GlobeNewsWire
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds Exclusive agreement...
5 months ago - GlobeNewsWire
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year
6 months ago - GlobeNewsWire
MIMEDX to Present at TD Cowen 44th Annual Health Care Conference
MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Healt...
6 months ago - GlobeNewsWire
MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth qu...
6 months ago - GlobeNewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx"or the "Company")(NASDAQ: MDXG). Such investors are advised to co...
7 months ago - PRNewsWire
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing
New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities New Credit Facilities Provide Substantial Interest Savings and ...
7 months ago - GlobeNewsWire
ROSEN, A TOP RANKED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
NEW YORK , Jan. 19, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, I...
7 months ago - PRNewsWire
MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MD...
7 months ago - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MiMedx Group, Inc...
7 months ago - Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company's ...
7 months ago - Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of investors concerning the Company...
7 months ago - Business Wire
MiMedx reports US FDA warning letter for Axiofill, shares drop
MiMedx Group said on Friday it had received a warning letter from the U.S. Food and Drug Administration related to the classification of its placental-derived tissue product Axiofill, and its shares f...
8 months ago - Reuters
MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net S...
8 months ago - GlobeNewsWire
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stoc...
8 months ago - GlobeNewsWire
MIMEDX to Highlight Published Data at SAWC Fall
MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on...
10 months ago - GlobeNewsWire
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the High Teens MARIETTA, Ga., Oct. 30, 2023 (GLOBE N...
10 months ago - GlobeNewsWire
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive a...
1 year ago - GlobeNewsWire
MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1
MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second qu...
1 year ago - GlobeNewsWire
